SCHEMBL5864240

SCHEMBL5864240

CCNC(=O)C1(CCCCN2CCN(c3ccc4c(c3)C(=O)N(Cc3cccc(F)c3)CC4)CC2)c2ccccc2Sc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 6/20 0.42
ATM Q13315 1/20 0.40
DRD3 P35462 6/20 0.40
DRD2 P14416 6/20 0.40
DRD1 P21728 2/20 0.40
LMNA P02545 1/20 0.39
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
DRD4 P21917 1/20 0.37
HTR1A P08908 2/20 0.35
HTR2A P28223 2/20 0.35
HTR2C P28335 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863993 0.98 ATM (0.41) HTR7ATMDRD3DRD2DRD1
SCHEMBL5863312 0.94 HTR7 (0.42) HTR7ATMDRD3DRD2LMNA
SCHEMBL5864287 0.93 DRD3 (0.44) HTR7DRD3DRD2DRD1LMNA
SCHEMBL5864275 0.93 DRD3 (0.41) HTR7DRD3DRD2DRD1DRD4
SCHEMBL5863749 0.93 LMNA (0.42) DRD3DRD2DRD1LMNAALDH1A1
SCHEMBL5864105 0.92 DRD3 (0.40) HTR7ATMDRD3DRD2DRD1
SCHEMBL5863901 0.92 HTR7 (0.42) HTR7DRD3DRD2DRD1LMNA
SCHEMBL5863660 0.92 ATM (0.41) HTR7ATMDRD3DRD2LMNA
SCHEMBL5864352 0.91 HTR7 (0.42) HTR7ATMDRD3DRD2DRD1
SCHEMBL5863801 0.91 DRD3 (0.43) HTR7ATMDRD3DRD2DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC HTR7 1820/4885ATM 3311/4885DRD3 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.